NASDAQ:AGEN - Agenus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 52.09 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.26
▼ -0.06 (-1.13%)
1 month | 3 months | 12 months
Get New Agenus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGEN

Average Price Target: $8.00
▲ +52.09% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Agenus in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 52.09% upside from the last price of $5.26.

Buy

The current consensus among 3 polled investment analysts is to buy stock in Agenus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2021B. RileyReiterated RatingBuy$8.00High
12/10/2020B. RileyReiterated RatingBuy$8.00Medium
9/23/2020William BlairReiterated RatingBuyLow
9/18/2020Jefferies Financial GroupBoost Price TargetBuy$5.00 ➝ $8.00Medium
6/22/2020B. RileyReiterated RatingBuy$6.00Low
6/5/2020B. RileyReiterated RatingBuy$6.00Low
5/29/2020B. RileyReiterated RatingBuy$6.00High
5/22/2020B. RileyReiterated RatingBuy$6.00Low
12/20/2019B. RileyInitiated CoverageBuy$6.00High
11/19/2019B. RileyInitiated CoverageBuy$6.00Low
4/22/2019B. RileyInitiated CoverageBuy ➝ Buy$5.00 ➝ $5.00Medium
8/4/2017Jefferies Financial GroupReiterated RatingBuy$7.00High
5/6/2017HC WainwrightSet Price TargetHold$5.00Low
4/23/2017Maxim GroupReiterated RatingBuy$7.00Medium
3/11/2017Maxim GroupSet Price TargetBuy$7.00Low
3/11/2017HC WainwrightSet Price TargetHold$5.00Low
2/16/2017HC WainwrightSet Price TargetHold$5.00N/A
12/1/2016JMP SecuritiesReiterated RatingBuyN/A
10/28/2016HC WainwrightDowngradeBuy ➝ Neutral$10.00 ➝ $5.00N/A
10/27/2016Maxim GroupReiterated RatingBuy$7.00N/A
8/23/2016Jefferies Financial GroupReiterated RatingBuyN/A
7/31/2016HC WainwrightReiterated RatingBuy$10.00N/A
7/29/2016Jefferies Financial GroupBoost Price TargetBuy$6.00 ➝ $7.00N/A
7/28/2016Maxim GroupReiterated RatingBuy$7.00N/A
6/22/2016Maxim GroupReiterated RatingBuyN/A
(Data available from 6/21/2016 forward)
Agenus logo
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $5.26
Low: $5.18
High: $5.38

50 Day Range

MA: $3.70
Low: $2.56
High: $5.32

52 Week Range

Now: $5.26
Low: $2.50
High: $5.95

Volume

6,911,700 shs

Average Volume

4,482,785 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Agenus?

The following sell-side analysts have issued stock ratings on Agenus in the last twelve months: B. Riley, Jefferies Financial Group Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for AGEN.

What is the current price target for Agenus?

2 Wall Street analysts have set twelve-month price targets for Agenus in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 52.1%. Jefferies Financial Group Inc. has the highest price target set, predicting AGEN will reach $8.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $8.00 for Agenus in the next year.
View the latest price targets for AGEN.

What is the current consensus analyst rating for Agenus?

Agenus currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGEN will outperform the market and that investors should add to their positions of Agenus.
View the latest ratings for AGEN.

What other companies compete with Agenus?

How do I contact Agenus' investor relations team?

Agenus' physical mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (781) 674-4400 and its investor relations email address is [email protected] The official website for Agenus is agenusbio.com.